52P MONITOR-UK: An initial analysis of a multi-centre, observational study of maintenance niraparib in ovarian cancer
Loading...
Contact
Check for full-text access
Issue Date
Type
Conference Proceedings
Language
Keywords
Alternative Title
Abstract
Background: Niraparib (PARP inhibitor) is approved in advanced ovarian cancer (OC) as maintenance therapy in the first line and recurrent platinum-sensitive settings. The MONITOR-UK study was designed to report real-world niraparib experience in UK clinical practice.
Description
Citation
Publisher
License
Journal
ESMO Open
Volume
Issue
27-29